via EPFL
Peptides represent a billion-dollar market in the pharmaceutical industry, but they can generally only be taken as injections to avoid degradation by stomach enzymes. Scientists at EPFL have now developed a method to generate peptides that resist enzymatic degradation and can be taken orally.
Peptides are short chains of amino acids that occur in our body, in plants or bacteria to control diverse functions. Several peptides are used as drugs such as insulin, which controls the metabolism of sugar, and cyclosporine, which suppresses organ rejection after transplants. More than 40 peptides are already approved as drugs, generating revenues in the billions. There are several hundreds of peptide-based medications currently in clinical trials.
But almost none of these drug-peptides can be taken orally. Since peptides are an important part of food, the stomach and intestines harbor countless enzymes that can degrade them, meaning that most peptide-based medication do not survive the passage through the gastrointestinal tract.
Hope to generate more stable peptides came from “cyclic” peptides, whose ends are joined together by chemical bridges making them more stable than linear ones because their backbones are less flexible and thus harder to attack by enzymes. In 2018, the research group of Christian Heinis at EPFL developed a peptide format termed double-bridged peptides, where peptides are cyclized by two chemical bridges that provide even higher stability. Despite its success, most such peptides were not sufficiently stable to survive the enormous enzymatic pressure found in the gastrointestinal tract.
Now, Heinis’s group has developed a new method that identifies among billions of double-bridged peptides those that bind a disease target of interest and survive enzymes of the gastrointestinal tract. The method is published in Nature Biomedical Engineering, and involves three steps.
First, billions of genetically encoded random peptide sequences are cyclized by two chemical bridges that impose conformational constraints onto the peptides’ backbones so that they are more difficult to attack by enzymes.
Second, this library of peptides is exposed to enzymes from cow intestine to eliminate all those peptides that are not stable.
In the third and last step, the scientist dip target proteins into the pool of surviving peptides to fish out those that bind to the wanted disease target. “It’s a bit like searching a needle in a haystack, and this method makes this easy,” says Heinis.
With this method, the researchers have succeeded for the first time in evolving target-specific peptides that can resist breakdown in the gastrointestinal tract. For example, they gave mice a lead peptide that inhibits thrombin – an important anti-thrombosis target – in the form of a pill. The peptide remained intact in the stomach and intestines, and even though it reached the blood stream in rather small quantities, most of it remained fully intact across the entire gastrointestinal tract. This is a key step towards engineering oral peptide drugs.
Heinis’s group is now applying the new method to develop oral peptides that act directly on gastrointestinal targets, meaning that they don’t need to travel into the blood stream. “We are focusing on chronic inflammatory diseases of the gastrointestinal tract like Crohn’s disease and ulcerative colitis as well as bacterial infections,” says Heinis. “We have already succeeded in generating enzyme-resistant peptides against the interleukin-23 receptor, an important target of these diseases, which affect millions of patients worldwide without any oral drug available.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Oral peptides
- Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024Phase 2b study in obesity expected to begin as planned in the fourth ...
- Endoscopy: Could Diabetes Medication Increase Gastric Contents Retention?
GLP1-RA drugs for diabetes may heighten risk of gastric retention during upper endoscopy. Read to find out more.
- 8 Health Benefits of Collagen
A collagen supplement may help smooth wrinkles, improve joint health, and support your gut. Here’s what health experts suggest you should know before trying it.
- Drug-Drug Interactions With Glucagon-like Peptide-1 Receptor Agonists
Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...
- Global Peptide Therapeutics Industry
Global Peptide Therapeutics Industry is valued at US$ 38.0 Bn for 2023 & expected to reach US$ 106.0 Bn by 2033 at a CAGR of 10.8% by 2033.
Go deeper with Google Headlines on:
Oral peptides
[google_news title=”” keyword=”oral peptides” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Peptide-based medications
- QULIPTA(TM) (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
QULIPTA is now the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent migraine across all frequencies, including episodic and chronic. Expanded ...
- QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first ...
- Will GLP-1 Drugs Wake up the Sleep Apnea Market?
This wildly popular new drug class is poised to disrupt several corners of the medical device world, including sleep apnea.
- What is Wegovy? Weight loss drug from the makers of Ozempic is now available in Canada. Here's what you should know
Ozempic was approved by Health Canada in 2018 specifically as a medication for people with type 2 diabetes. Weight loss can be a byproduct of taking Ozempic, whereas Wegovy is a slightly higher dose ...
- C-Peptide Index may Predict endogenous insulin secretory capacity under non-fasting conditions: Study
Researchers have found that the C-peptide index (CPI) at 2 hours post-meal is a significant indicator of endogenous insulin secretory capacity in patients with type 2 diabetes, according to a ...
Go deeper with Google Headlines on:
Peptide-based medications
[google_news title=”” keyword=”peptide-based medications” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]